DF/HCC Program Affiliation

Research Abstract

Publications

• Lipshultz SE, Giantris AL, Lipsitz SR, Kimball Dalton V, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE, Colan SD.Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farb
  11896119
• Moran AM, Lipshultz SE, Rifai N, O'Brien P, Mooney H, Perry S, Perez-Atayde A, Lipsitz SR, Colan SD.Non-invasive assessment of rejection in pediatric transplant patients: serologic and echocardiographic prediction of biopsy-proven myocardial rejection.J H
  10967269
• Nysom K, Holm K, Lipsitz SR, Mone SM, Colan SD, Orav EJ, Sallan SE, Olsen JH, Hertz H, Jacobsen JR, Lipshultz SE.Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.J Clin Oncol 1998 Feb;16(
  9469339
• Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, Orav EJ, Gelber RD, Colan SD.Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.N Engl J Med 1995 Jun 29;332(26):1738-43.
  7760889
• Lipshultz SE, Sanders SP, Goorin AM, Krischer JP, Sallan SE, Colan SD.Monitoring for anthracycline cardiotoxicity.Pediatrics 1994 Mar;93(3):433-7.
  7818624
• Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP.Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.N Engl J Med 1991 Mar 21;324(12):808-15.
  1997853
• Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R, Freedman MH, Nathan DG.Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.N Engl J Med 1985 Jun 20;312(25):1600-3.
  4000198